Richard Mularski to Immunogenicity, Vaccine
This is a "connection" page, showing publications Richard Mularski has written about Immunogenicity, Vaccine.
Connection Strength
0.053
-
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial. Lancet Infect Dis. 2023 02; 23(2):233-246.
Score: 0.053